8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Mar 17, 2026·SEC
Bluejay Diagnostics, Inc.(BJDX)Earnings, Financials & Key Ratios
BJDX•NASDAQ
Price updated Jun 19, 2026
AboutBluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.Show more
- Revenue$0
- EBITDA-$7M+2.7%
- Net Income-$7M+11.3%
- EPS (Diluted)-15.25+96.7%
- ROE-117.02%+34.6%
BJDX Key Insights
Bluejay Diagnostics, Inc. (BJDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Profits declining 43.5% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BJDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BJDX Price & Volume
Bluejay Diagnostics, Inc. (BJDX) stock price & volume — 10-year historical chart
Loading chart...
BJDX Growth Metrics
Bluejay Diagnostics, Inc. (BJDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM4.83%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM97.06%
Return on Capital
10 Years-3007.93%
5 Years-101.07%
3 Years-138.46%
Last Year-117.38%
BJDX Recent Earnings
Bluejay Diagnostics, Inc. (BJDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (43%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$1.95
—
Rev
—
—
Q2 2026
Mar 6, 2026Metric
Actual
Est
EPS
$2.37
—
Rev
—
—
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$4.04
—
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.41
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.95 | — |
| Q2 2026 | Mar 6, 2026 | $2.37 | — |
| Q4 2025 | Nov 7, 2025 | $4.04 | — |
| Q3 2025 | Aug 7, 2025 | $1.41 | — |
Based on last 12 quarters of dataView full earnings history →
BJDX Peer Comparison
Bluejay Diagnostics, Inc. (BJDX) competitors in Patient monitoring and wearable diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 QDEL | 930.68M | 13.67 | -0.82 | -1.89% | -45.57% | -56.31% | 1.46 | |
 CUE | 74.79M | 28.46 | -3.39 | 195.75% | -59.65% | -98.3% | 0.16 | |
 LFMD | 229.72M | 4.75 | -20.65 | -8.66% | -7.76% | -162.38% | 0.27 | |
 IDXX | 44.64B | 562.09 | 42.97 | 10.42% | 24.63% | 70.87% | 0.67 | |
 OSUR | 305.85M | 4.25 | -4.52 | -38.1% | -61.93% | -15.09% | 0.04 | |
 CHEK | 10.88M | 1.86 | -0.43 | -226.19% | ||||
 TNXP | 191.45M | 12.01 | -0.82 | 29.85% | -8.4% | -67.65% | 0.01 | |
 DHR | 125.4B | 177.17 | 35.15 | 2.9% | 14.89% | 7.06% | 0.35 |
Compare BJDX vs Peers
Bluejay Diagnostics, Inc. (BJDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BJDX Income Statement
Bluejay Diagnostics, Inc. (BJDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 249.04K | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | -100% | - | - | - |
Cost of Goods Sold | 142.97K | 157.04K | 0 | 200.13K | 0 | 0 | 0 | 98.37K |
COGS % of Revenue | - | - | - | 80.36% | - | - | - | - |
Gross Profit | -142.97K▲ 0% | -157.04K▼ 9.8% | 0▲ 100.0% | 48.91K▲ 0% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | -98.37K▲ 0% |
Gross Margin % | - | - | - | 19.64% | - | - | - | - |
Gross Profit Growth % | - | -9.84% | 100% | - | -100% | - | - | - |
Operating Expenses | 1.49M | 1.04M | 3.23M | 9.37M | 10.31M | 7.17M | 6.95M | 6.9M |
OpEx % of Revenue | - | - | - | 3761.12% | - | - | - | - |
Selling, General & Admin | 1.18M | 669.14K | 2.08M | 5.21M | 4.6M | 3.7M | 3.91M | 3.93M |
SG&A % of Revenue | - | - | - | 2093.85% | - | - | - | - |
Research & Development | 454.61K | 527.25K | 1.15M | 4.15M | 5.71M | 3.47M | 3.05M | 3.07M |
R&D % of Revenue | - | - | - | 1667.26% | - | - | - | - |
Other Operating Expenses | -142.97K | -157.04K | 0 | 0 | 0 | 0 | 0 | -98.37K |
Operating Income | -1.63M▲ 0% | -1.2M▲ 26.7% | -3.23M▼ 170.0% | -9.32M▼ 188.5% | -10.31M▼ 10.7% | -7.17M▲ 30.5% | -6.95M▲ 3.0% | -7M▲ 0% |
Operating Margin % | - | - | - | -3741.48% | - | - | - | - |
Operating Income Growth % | - | 26.67% | -169.99% | -188.46% | -10.66% | 30.47% | 3.02% | - |
EBITDA | -1.49M | -1.04M | -3.08M | -9.01M | -9.53M | -6.97M | -6.78M | -6.83M |
EBITDA Margin % | - | - | - | -3618.46% | - | - | - | - |
EBITDA Growth % | - | 30.17% | -196.77% | -192.16% | -5.76% | 26.86% | 2.7% | -6.18% |
D&A (Non-Cash Add-back) | 142.97K | 157.04K | 145.72K | 306.37K | 780.96K | 199.1K | 170.68K | 168.35K |
EBIT | -1.63M | -1.2M | -3.12M | -9.32M | -9.95M | -6.89M | -6.85M | -6.92M |
Net Interest Income | 52.28K | 116.67K | 145.84K | 89.67K | 164.9K | -677.21K | 96.72K | 98.01K |
Interest Income | 52.28K | 143.67K | 513.3K | 89.67K | 164.9K | 145.82K | 97.56K | 98.62K |
Interest Expense | 0 | 27K | 367.46K | 0 | 0 | 823.03K | 839 | 609 |
Other Income/Expense | 811.57K | 38.11K | -258.13K | 20.83K | 357.33K | -548.18K | 104.49K | 96.72K |
Pretax Income | -819.84K▲ 0% | -1.16M▼ 41.3% | -3.49M▼ 201.2% | -9.3M▼ 166.5% | -9.95M▼ 7.1% | -7.72M▲ 22.5% | -6.85M▲ 11.3% | -6.9M▲ 0% |
Pretax Margin % | - | - | - | -3733.11% | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -757.72K▲ 0% | -1.13M▼ 48.6% | -3.73M▼ 231.3% | -9.3M▼ 149.3% | -9.95M▼ 7.1% | -7.72M▲ 22.5% | -6.85M▲ 11.3% | -6.9M▲ 0% |
Net Margin % | - | - | - | -3733.11% | - | - | - | - |
Net Income Growth % | - | -48.57% | -231.32% | -149.27% | -7.07% | 22.46% | 11.26% | 4.83% |
Net Income (Continuing) | -819.84K | -1.16M | -3.49M | -9.3M | -9.95M | -7.72M | -6.85M | -6.9M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -38.20▲ 0% | -56.76▼ 48.6% | -118.68▼ 109.1% | -292.88▼ 146.8% | -290.48▲ 0.8% | -456.76▼ 57.2% | -15.25▲ 96.7% | -15.37▲ 0% |
EPS Growth % | - | -48.59% | -109.09% | -146.78% | 0.82% | -57.24% | 96.66% | 97.06% |
EPS (Basic) | -38.20 | -56.76 | -118.68 | -292.88 | -290.48 | -456.76 | -15.25 | - |
Diluted Shares Outstanding | 19.84K | 19.84K | 31.43K | 31.51K | 34.27K | 45.85K | 449.04K | 449.04K |
Basic Shares Outstanding | 19.84K | 19.84K | 31.43K | 31.51K | 34.27K | 45.85K | 449.04K | 449.04K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
BJDX Balance Sheet
Bluejay Diagnostics, Inc. (BJDX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 300.34K | 1.06M | 20.66M | 11.79M | 3.22M | 4.9M | 5.46M | 3.97M |
Cash & Short-Term Investments | 96.01K | 912.36K | 19.05M | 10.11M | 2.21M | 4.3M | 5.16M | 3.68M |
Cash Only | 96.01K | 912.36K | 19.05M | 10.11M | 2.21M | 4.3M | 5.16M | 3.68M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 645 | 0 | 0 | 0 | 41.27K | 14.56K | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 123.51K | 84.76K | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 315.3 | 197.01 | - | - | - | - | - | - |
Other Current Assets | 69.92K | 0 | 0 | 0 | 223.81K | -14.56K | 298.73K | 283K |
Total Non-Current Assets | 616.18K | 459.14K | 358.38K | 1.73M | 1.65M | 1.76M | 1.66M | 1.63M |
Property, Plant & Equipment | 611.56K | 459.14K | 332.75K | 1.7M | 1.62M | 1.72M | 1.65M | 1.62M |
Fixed Asset Turnover | - | - | - | 0.15x | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 4.62K | 4.62K | 4.62K | 4.46K | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | -4.62K | 21.02K | 30.75K | 28.66K | 35.26K | 7.91K | 10.83K |
Total Assets | 916.52K▲ 0% | 1.52M▲ 65.6% | 21.02M▲ 1285.3% | 13.52M▼ 35.7% | 4.87M▼ 64.0% | 6.66M▲ 36.7% | 7.12M▲ 6.9% | 5.6M▲ 0% |
Asset Turnover | - | - | - | 0.02x | - | - | - | 0.00x |
Asset Growth % | - | 65.55% | 1285.25% | -35.67% | -63.99% | 36.74% | 6.94% | -69.48% |
Total Current Liabilities | 576.54K | 1.85M | 637.16K | 1.64M | 1.77M | 810.37K | 1.12M | 1.41M |
Accounts Payable | 29.13K | 374.93K | 295.78K | 635.82K | 491.47K | 145.12K | 214.25K | 220.29K |
Days Payables Outstanding | 74.35 | 871.43 | - | 1.16K | - | - | - | 653.55 |
Short-Term Debt | 265K | 1.06M | 0 | 0 | 0 | 113.26K | 100K | 97.03K |
Deferred Revenue (Current) | 86K | 258.92K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 196.41K | 21.81K | 0 | 4.81K | 4.81K | 4.81K | 804.94K | 1.1M |
Current Ratio | 0.52x | 0.57x | 32.43x | 7.19x | 1.82x | 6.05x | 4.88x | 2.81x |
Quick Ratio | 0.31x | 0.53x | 32.43x | 7.19x | 1.82x | 6.05x | 4.88x | 2.81x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 3.27M | 3.88M | 0 | 339.74K | 202.31K | 117.56K | 24.75K | 3.49K |
Long-Term Debt | 804.29K | 0 | 0 | 0 | 0 | 0 | 20.21K | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 323.92K | 189.99K | 108.99K | 0 | 139.71K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2.47M | 3.88M | 0 | 15.82K | 12.32K | 8.57K | 4.54K | 3.49K |
Total Liabilities | 3.85M | 5.72M | 637.16K | 1.98M | 1.97M | 927.92K | 1.14M | 1.42M |
Total Debt | 1.07M | 1.06M | 0 | 492.62K | 352.98K | 222.25K | 120.21K | 97.03K |
Net Debt | 973.28K | 143.55K | -19.05M | -9.62M | -1.86M | -4.08M | -5.04M | -3.59M |
Debt / Equity | - | - | - | 0.04x | 0.12x | 0.04x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.53x |
Interest Coverage | - | -44.32x | -8.49x | - | - | -8.38x | -8161.67x | -11361.89x |
Total Equity | -2.93M▲ 0% | -4.21M▼ 43.4% | 20.38M▲ 584.6% | 11.54M▼ 43.4% | 2.89M▼ 74.9% | 5.73M▲ 97.9% | 5.98M▲ 4.3% | 4.18M▲ 0% |
Equity Growth % | - | -43.44% | 584.57% | -43.37% | -74.92% | 97.92% | 4.29% | -74.8% |
Book Value per Share | -147.84 | -212.06 | 648.58 | 366.32 | 84.48 | 124.97 | 13.31 | 9.31 |
Total Shareholders' Equity | -2.93M | -4.21M | 20.38M | 11.54M | 2.89M | 5.73M | 5.98M | 4.18M |
Common Stock | 315 | 315 | 2.01K | 2.02K | 124 | 55 | 60 | 103 |
Retained Earnings | -2.93M | -4.21M | -7.69M | -17M | -26.95M | -34.67M | -41.52M | -43.44M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2.47M | -3.88M | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BJDX Cash Flow Statement
Bluejay Diagnostics, Inc. (BJDX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.69M | -508.71K | -4.37M | -7.74M | -8.31M | -7.82M | -6.05M | -6.46M |
Operating CF Margin % | - | - | - | -3108.57% | - | - | - | - |
Operating CF Growth % | - | 69.9% | -758.4% | -77.28% | -7.39% | 5.94% | 22.59% | 2.07% |
Net Income | -819.84K | -1.16M | -3.49M | -9.3M | -9.95M | -7.72M | -6.85M | -6.9M |
Depreciation & Amortization | 142.97K | 157.04K | 145.72K | 306.37K | 780.96K | 199.1K | 170.68K | 168.35K |
Stock-Based Compensation | 14.81K | 7.37K | 68.46K | 433K | 189.25K | 20.09K | 6 | -1.49K |
Deferred Taxes | 0 | 0 | 170.66K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -849.78K | -111.1K | 222.01K | 237.45K | 3.09K | 312.03K | 42.94K | 46K |
Working Capital Changes | -178.28K | 596.26K | -1.49M | 578.54K | 666.73K | -633.19K | 581.28K | 232.51K |
Change in Receivables | -645 | 645 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | -103.88K | 38.75K | 84.76K | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -25.21K | 345.8K | -79.15K | 298.88K | -235.76K | -346.35K | 69.13K | -299.24K |
Cash from Investing | -6.02K | 0 | -23.95K | -1.2M | -704.17K | -306.78K | -173.74K | -189.05K |
Capital Expenditures | -6.02K | 0 | -23.95K | -1.2M | -704.17K | -306.78K | -173.74K | -192.72K |
CapEx % of Revenue | - | - | - | 481.56% | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.67K |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 1.51M | 1.33M | 22.53M | 8.07K | 1.11M | 10.22M | 7.09M | 7.22M |
Debt Issued (Net) | -265K | 270K | 4.2M | -801 | -4.81K | -4.81K | -4.03K | -4.09K |
Equity Issued (Net) | 1.68M | 1.06M | 18.86M | 8.88K | 159.84K | 12.07M | 7.09M | 7.68M |
Dividends Paid | 0 | 0 | -17.67K | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 100K | 0 | -513.47K | 0 | 956.53K | -1.84M | 0 | -464.67K |
Net Change in Cash | -184.34K▲ 0% | 816.35K▲ 542.9% | 18.14M▲ 2121.5% | -8.93M▼ 149.3% | -7.91M▲ 11.5% | 2.09M▲ 126.5% | 862.93K▼ 58.8% | 568.35K▲ 0% |
Free Cash Flow | -1.7M▲ 0% | -508.71K▲ 70.0% | -4.39M▼ 763.1% | -8.94M▼ 103.6% | -9.02M▼ 0.9% | -8.13M▲ 9.9% | -6.23M▲ 23.4% | -6.65M▲ 0% |
FCF Margin % | - | - | - | -3590.13% | - | - | - | - |
FCF Growth % | - | 70.01% | -763.11% | -103.63% | -0.86% | 9.89% | 23.37% | 4.66% |
FCF per Share | -85.51 | -25.65 | -139.72 | -283.78 | -263.18 | -177.25 | -13.87 | -14.81 |
FCF Conversion (FCF/Net Income) | 2.23x | 0.45x | 1.17x | 0.83x | 0.84x | 1.01x | 0.88x | 0.96x |
Interest Paid | 46.07K | 53.24K | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BJDX Key Ratios
Bluejay Diagnostics, Inc. (BJDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -46.12% | -58.25% | -137.9% | -178.98% | -117.02% | -144.27% |
Return on Invested Capital (ROIC) | - | - | -429.68% | -522.84% | -399.92% | -404.18% | -621.94% |
Gross Margin | - | - | 19.64% | - | - | - | - |
Net Margin | - | - | -3733.11% | - | - | - | - |
Debt / Equity | - | - | 0.04x | 0.12x | 0.04x | 0.02x | 0.02x |
Interest Coverage | -44.32x | -8.49x | - | - | -8.38x | -8161.67x | -11361.89x |
FCF Conversion | 0.45x | 1.17x | 0.83x | 0.84x | 1.01x | 0.88x | 0.96x |
Revenue Growth | - | - | - | -100% | - | - | - |
Related:BJDX Dividend History·BJDX Revenue History·BJDX Price History·BJDX P/E History·BJDX Financial Ratios·BJDX Institutional Holders
BJDX SEC Filings & Documents
Bluejay Diagnostics, Inc. (BJDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BJDX Frequently Asked Questions
Bluejay Diagnostics, Inc. (BJDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bluejay Diagnostics, Inc. (BJDX) grew revenue by 0.0% over the past year. Growth has been modest.
Bluejay Diagnostics, Inc. (BJDX) reported a net loss of $6.9M for fiscal year 2025.
Dividend & Returns
Bluejay Diagnostics, Inc. (BJDX) has a return on equity (ROE) of -117.0%. Negative ROE indicates the company is unprofitable.
Bluejay Diagnostics, Inc. (BJDX) had negative free cash flow of $6.7M in fiscal year 2025, likely due to heavy capital investments.